Prevalence of Mpox Vaccine Acceptance and Hesitancy Among People Living with HIV: a Comprehensive Systematic Review and Meta-analysis

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2025 Mar 8

PMID 40057788

Authors

Ambanna Yappalparvi

Mahalaqua Nazli Khatib

Ashok Kumar Balaraman

M M Rekha

Mandeep Kaur

Girish Chandra Sharma

Puneet Sudan

K Satyam Naidu

Rajesh Singh

Sonam Ramashankar

Karan Khati

Sanjay Singh Chauhan

Lokesh Verma

Amritpal Sidhu

Rachana Mehta

Renu Sah

Abhay M Gaidhane

Muhammed Shabil

Joseph Clement Chipeta

Ganesh Bushi

Affiliations

Soon will be listed here.

Abstract

Background: Vaccine acceptance among People Living with HIV (PLWH) is crucial for managing and mitigating the spread of infectious diseases, including Mpox. This systematic review and meta-analysis assess the rate of vaccine acceptance for Mpox among PLWH and identify factors influencing these rates.

Methods: We searched major databases including PubMed, Embase, and Web of Science up to 30 August 2024 for observational studies involving PLWH that reported on mpox vaccine acceptance rates. A random-effects model was employed for the meta-analysis, utilizing R software version 4.4. Heterogeneity among the studies was quantified using the I² statistic, and the methodological quality of each study was assessed using a modified version of the Newcastle-Ottawa Scale.

Results: Out of 1,123 articles identified, 17 studies met the inclusion criteria and included 7,248 participants. The pooled estimate of the Mpox vaccine acceptance rate was 61.1% (95% CI: 44.2-75.7%), with high heterogeneity (I² = 99%). Additionally, a pooled vaccine hesitancy prevalence was 13.2%, (95% CI: 2.4-48.6%), reflecting substantial variability and had high heterogeneity (I² = 98%).

Conclusion: This systematic review and meta-analysis reveal moderate Mpox vaccine acceptance and considerable hesitancy among PLWH. To further increase vaccine uptake and address any remaining hesitancy in this at-risk population, targeted public health strategies and ongoing research are necessary. Strengthening vaccine acceptance is critical to safeguarding PLWH against emerging infectious diseases such as Mpox.

Clinical Trial Number: Not applicable.

References

Mercer J, Helenius A . Virus entry by macropinocytosis. Nat Cell Biol. 2009; 11(5):510-20. DOI: 10.1038/ncb0509-510. View

Dukers-Muijrers N, Evers Y, Widdershoven V, Davidovich U, Adam P, Op de Coul E . Mpox vaccination willingness, determinants, and communication needs in gay, bisexual, and other men who have sex with men, in the context of limited vaccine availability in the Netherlands (Dutch Mpox-survey). Front Public Health. 2023; 10:1058807. PMC: 9850232. DOI: 10.3389/fpubh.2022.1058807. View

Newman P, Logie C . HIV vaccine acceptability: a systematic review and meta-analysis. AIDS. 2010; 24(11):1749-56. DOI: 10.1097/qad.0b013e32833adbe8. View

Whetten K, Reif S, Whetten R, Murphy-McMillan L . Trauma, mental health, distrust, and stigma among HIV-positive persons: implications for effective care. Psychosom Med. 2008; 70(5):531-8. DOI: 10.1097/PSY.0b013e31817749dc. View

Leon-Figueroa D, Barboza J, Valladares-Garrido M, Sah R, Rodriguez-Morales A . Prevalence of intentions to receive monkeypox vaccine. A systematic review and meta-analysis. BMC Public Health. 2024; 24(1):35. PMC: 10763398. DOI: 10.1186/s12889-023-17473-y. View

Furuya-Kanamori L, Barendregt J, Doi S . A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018; 16(4):195-203. DOI: 10.1097/XEB.0000000000000141. View

Cribbs S, Crothers K, Morris A . Pathogenesis of HIV-Related Lung Disease: Immunity, Infection, and Inflammation. Physiol Rev. 2019; 100(2):603-632. DOI: 10.1152/physrev.00039.2018. View

Lin K, Chen G, Lee Y, Huang Y, Cheng A, Sun H . Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review. World J Gastroenterol. 2017; 23(20):3589-3606. PMC: 5449416. DOI: 10.3748/wjg.v23.i20.3589. View

Helenius A . Virus Entry: Looking Back and Moving Forward. J Mol Biol. 2018; 430(13):1853-1862. PMC: 7094621. DOI: 10.1016/j.jmb.2018.03.034. View

10.

Abara W, Sullivan P, Carpino T, Sanchez T, Atkins K, Delaney K . Characteristics of Mpox Vaccine Recipients Among a Sample of Men Who Have Sex With Men With Presumed Exposure to Mpox. Sex Transm Dis. 2023; 50(7):458-461. PMC: 10330397. DOI: 10.1097/OLQ.0000000000001800. View

11.

Liu J, Liu S, Yu S, Du X, Hao J, Hui R . Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis. BMC Public Health. 2024; 24(1):1878. PMC: 11247826. DOI: 10.1186/s12889-024-19260-9. View

12.

Johnson T, Klepser D, Bares S, Scarsi K . Predictors of vaccination rates in people living with HIV followed at a specialty care clinic. Hum Vaccin Immunother. 2020; 17(3):791-796. PMC: 7993128. DOI: 10.1080/21645515.2020.1802163. View

13.

Araoz-Salinas J, Ortiz-Saavedra B, Ponce-Rosas L, Soriano-Moreno D, Soriano-Moreno A, Alave J . Perceptions and Intention to Get Vaccinated against Mpox among the LGBTIQ+ Community during the 2022 Outbreak: A Cross-Sectional Study in Peru. Vaccines (Basel). 2023; 11(5). PMC: 10220940. DOI: 10.3390/vaccines11051008. View

14.

Reyes-Uruena J, DAmbrosio A, Croci R, Bluemel B, Cenciarelli O, Pharris A . High monkeypox vaccine acceptance among male users of smartphone-based online gay-dating apps in Europe, 30 July to 12 August 2022. Euro Surveill. 2022; 27(42). PMC: 9585877. DOI: 10.2807/1560-7917.ES.2022.27.42.2200757. View

15.

Zucman D, Fourn E, Touche P, Majerholc C, Vallee A . Monkeypox Vaccine Hesitancy in French Men Having Sex with Men with PrEP or Living with HIV in France. Vaccines (Basel). 2022; 10(10). PMC: 9609833. DOI: 10.3390/vaccines10101629. View

16.

MacGibbon J, Cornelisse V, Smith A, Broady T, Hammoud M, Bavinton B . Mpox (monkeypox) knowledge, concern, willingness to change behaviour, and seek vaccination: results of a national cross-sectional survey. Sex Health. 2023; 20(5):403-410. DOI: 10.1071/SH23047. View

17.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

18.

Fu L, Sun Y, Li Y, Wang B, Yang L, Tian T . Perception of and Vaccine Readiness towards Mpox among Men Who Have Sex with Men Living with HIV in China: A Cross-Sectional Study. Vaccines (Basel). 2023; 11(3). PMC: 10059946. DOI: 10.3390/vaccines11030528. View

19.

Sagy Y, Zucker R, Hammerman A, Markovits H, Arieh N, Abu Ahmad W . Real-world effectiveness of a single dose of mpox vaccine in males. Nat Med. 2023; 29(3):748-752. PMC: 9930701. DOI: 10.1038/s41591-023-02229-3. View

20.

Peretti-Watel P, Larson H, Ward J, Schulz W, Verger P . Vaccine hesitancy: clarifying a theoretical framework for an ambiguous notion. PLoS Curr. 2015; 7. PMC: 4353679. DOI: 10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289. View